

## Special Issue

# Innovative Immunotherapies: CAR-T Cell Therapy for Cancers: 2nd Edition

### Message from the Guest Editor

Immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Innovative immunotherapies, such as CAR-T, have shown advantageous outcomes in various cancer types. By modifying a patient's T cells, CAR-T targets specific antigens in cancer cells. This precision targeting allows for a particular attack on cancer cells while minimizing damage to healthy cells. However, it is important to note that CAR-T therapy has some difficulties and challenges; for example, it can be associated with significant side effects, including cytokine release syndrome and neurotoxicity. Improving CAR-T involves better target selection, higher potency, longer persistence, and overcoming resistance mechanisms that are employed by cancer cells to evade/escape the immune system. In this Special Issue, we will encourage novel approaches and perspectives of CAR-T cell therapy for cancers.

---

### Guest Editor

Dr. Shebli Atrash

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC 28204, USA

---

### Deadline for manuscript submissions

14 August 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/233737](https://mdpi.com/si/233737)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)